Patents by Inventor David S. Weinstein

David S. Weinstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20180325899
    Abstract: Compounds of formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: November 17, 2016
    Publication date: November 15, 2018
    Inventors: David S. Weinstein, Ryan M. Moslin, Yanlei Zhang, Daniel S. Gardner, Joseph B. Santella, Charles M. Langevine, Sylwia Stachura
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20180265504
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 20, 2018
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
  • Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
    Patent number: 10000480
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: June 19, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
  • PHOSPHINE OXIDE ALKYL AMIDE SUBSTITUTED HETEROARYL COMPOUNDS AS MODULATORS OF IL-12, IL-23, AND/OR IFN ALPHA RESPONSES
    Publication number: 20180162889
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: December 12, 2017
    Publication date: June 14, 2018
    Inventors: Michael G. YANG, Zili Xiao, John V. Duncia, David S. Weinstein
  • Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 9987266
    Abstract: Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: June 5, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman, Chunjian Liu
  • Imidazole-derived modulators of the glucocorticoid receptor
    Patent number: 9796720
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: October 24, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael G. Yang, Zili Xiao, David S. Weinstein
  • ROR? modulators
    Patent number: 9725443
    Abstract: Described are ROR? modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: August 8, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: T. G. Murali Dhar, Jingwu Duan, Hua Gong, Bin Jiang, Zhonghui Lu, David S. Weinstein
  • ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES
    Publication number: 20170209426
    Abstract: Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: April 6, 2017
    Publication date: July 27, 2017
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman, Chunjian Liu
  • Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 9663467
    Abstract: Compounds having the following formula (I): or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: May 30, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman, Chunjian Liu
  • ROR? modulators
    Patent number: 9663469
    Abstract: Described are ROR? modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: May 30, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: T. G. Murali Dhar, Jingwu Duan, Hua Gong, Bin Jiang, Zhonghui Lu, David S. Weinstein
  • Imide and acylurea derivatives as modulators of the glucocorticoid receptor
    Patent number: 9593113
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-KB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: March 14, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: David S. Weinstein, Hua Gong, Michael G Yang, Zili Xiao
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20170022192
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: October 10, 2016
    Publication date: January 26, 2017
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
  • Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFN?
    Patent number: 9540333
    Abstract: Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: January 10, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joseph B. Santella, Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski
  • Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 9505748
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: November 29, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Shuqun Lin, Steven H. Spergel, Yanlei Zhang
  • RORy MODULATORS
    Publication number: 20160318870
    Abstract: Described are ROR? modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Application
    Filed: September 8, 2014
    Publication date: November 3, 2016
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: T.G Murali Dhar, Jingwu Duan, Hua Gong, Bin Jiang, Zhonghui Lu, David S. Weinstein
  • IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES
    Publication number: 20160304524
    Abstract: Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: December 10, 2014
    Publication date: October 20, 2016
    Inventors: Chunjian Liu, James Lin, Ryan M. Moslin, David S. Weinstein, John S. Tokarski
  • ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES
    Publication number: 20160280649
    Abstract: Compounds having the following formula (I): or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: January 16, 2014
    Publication date: September 29, 2016
    Inventors: Ryan M. MOSLIN, David S. WEINSTEIN, Stephen T. WROBLESKI, Yanlei ZHANG, John S. TOKARSKI, Michael E. MERTZMAN, Chunjian LIU
  • RORgamma MODULATORS
    Publication number: 20160229844
    Abstract: Described are ROR? modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Application
    Filed: September 18, 2014
    Publication date: August 11, 2016
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: T. G. Murali Dhar, Jingwu Duan, Hua Gong, Bin Jiang, Zhonghui Lu, David S. Weinstein
  • IMIDAZOLE-DERIVED MODULATORS OF THE GLUCOCORTICOID RECEPTOR
    Publication number: 20160200728
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-kB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification.
    Type: Application
    Filed: August 21, 2014
    Publication date: July 14, 2016
    Inventors: Michael G. Yang, Zili Xiao, David S. Weinstein
  • IMIDE AND ACYLUREA DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR
    Publication number: 20160185776
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-KB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification.
    Type: Application
    Filed: August 21, 2014
    Publication date: June 30, 2016
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: David S. Weinstein, Hua Gong, Michael G Yang, Zili Xiao